Suppliers and packagers for ESTROGEL

ESTROGEL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ascend Theraps Us	ESTROGEL	estradiol	GEL, METERED;TRANSDERMAL	021166	NDA	ASCEND Therapeutics US, LLC	17139-617-40	50 g in 1 BOTTLE, PUMP (17139-617-40)	2004-02-09
Ascend Theraps Us	ESTROGEL	estradiol	GEL;TOPICAL	021166	NDA	ASCEND Therapeutics US, LLC	17139-617-40	50 g in 1 BOTTLE, PUMP (17139-617-40)	2004-02-09

ESTROGEL Pharmaceutical Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers involved in the manufacturing and distribution of ESTROGEL, a transdermal estradiol gel used for hormone replacement therapy. The analysis focuses on primary active pharmaceutical ingredient (API) manufacturers, excipient providers, packaging material suppliers, and contract manufacturing organizations (CMOs) critical to ESTROGEL's market presence. Understanding these supply chain components is vital for assessing production continuity, cost structure, and potential risks.

What is ESTROGEL?

ESTROGEL is a prescription medication containing estradiol, a synthetic form of estrogen. It is formulated as a topical gel and is used to treat moderate to severe symptoms of menopause, such as hot flashes and vaginal dryness, by delivering estrogen directly through the skin. The active ingredient is estradiol, and the formulation requires specific excipients to ensure stability, delivery, and absorption.

Who Manufactures the Active Pharmaceutical Ingredient (API) for ESTROGEL?

The primary active pharmaceutical ingredient for ESTROGEL is estradiol. The production of estradiol API is a complex chemical synthesis process. Manufacturers specializing in steroid hormones are typically involved. While specific API suppliers are often proprietary information protected by supply agreements and confidentiality clauses, publicly available information and patent filings offer insights into potential sources and the regulatory landscape governing API production.

The manufacturing of estradiol API must adhere to stringent Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous quality control measures for purity, potency, and the absence of contaminants.

Potential API manufacturers are generally large chemical synthesis companies with expertise in steroid chemistry and a strong regulatory compliance record. These companies often operate globally to serve the pharmaceutical industry. The supply of estradiol API is critical, and drug manufacturers typically maintain multiple qualified suppliers to mitigate supply chain disruptions.

Which Excipients Are Essential for ESTROGEL Formulation?

ESTROGEL's transdermal gel formulation requires a specific blend of excipients to achieve the desired drug delivery profile, stability, and patient usability. Key excipients include:

• Solvents/Carriers: These facilitate the dissolution of estradiol and its absorption through the skin. Common solvents in transdermal systems include ethanol and isopropyl alcohol.

  • Ethanol: Typically, pharmaceutical-grade anhydrous ethanol is used. Major global producers of industrial and pharmaceutical alcohols include companies like The Chemours Company and BASF SE.
  • Isopropyl Alcohol (IPA): USP-grade IPA is also a common solvent. Suppliers include Dow Chemical Company and LyondellBasell Industries N.V.

• Gelling Agents: These are responsible for the gel consistency, allowing for controlled application and adherence to the skin.

  • Carbomers (e.g., Carbopol): These are synthetic polymers that form clear gels in the presence of a neutralizing agent. Lubrizol Corporation is a primary supplier of Carbopol polymers.

• Neutralizing Agents: Used to neutralize the carbomer gelling agent, forming the gel matrix.

  • Triethanolamine (TEA): A common neutralizing agent for carbomers. Dow Chemical Company and BASF SE are significant suppliers of TEA.

• Emollients/Humectants: These enhance skin feel, prevent drying of the gel, and can aid in skin penetration.

  • Propylene Glycol: Widely used for its humectant and solvent properties. Major suppliers include Dow Chemical Company and LyondellBasell Industries N.V.
  • Glycerin: Another common humectant. Producers include BASF SE and Croda International Plc.

• Preservatives: To prevent microbial contamination of the product during storage.

  • Methylparaben and Propylparaben: Often used in combination. Suppliers of parabens include Clariant AG and Jeen International Corporation.

The selection and sourcing of these excipients are critical. Pharmaceutical companies must qualify their excipient suppliers through rigorous audits and testing to ensure compliance with pharmacopoeial standards (e.g., USP, EP) and GMP. The quality and consistency of excipients directly impact the final drug product's safety, efficacy, and shelf life.

Who Provides Packaging Materials for ESTROGEL?

ESTROGEL is typically packaged in specific dispensing devices that ensure accurate dosing and prevent contamination. Common packaging components include:

• Primary Packaging: Materials in direct contact with the drug product.

  • Dosing Pumps/Applicators: These are often specialized plastic devices designed for precise gel dispensing. Manufacturers of such precision dispensing systems are key. Companies like AptarGroup, Inc., which specializes in drug delivery devices, are likely involved in supplying such components for transdermal products.
  • Internal Bladders/Containers: The gel may be housed in a flexible bladder or container within the pump system, often made of specific polymers that are inert and compatible with the gel formulation. Materials like polyethylene or polypropylene from major polymer manufacturers such as LyondellBasell Industries N.V. or SABIC could be utilized.

• Secondary Packaging: Outer packaging for protection and information.

  • Cartons: Made from paperboard, supplied by packaging converters like WestRock Company or Amcor plc.
  • Leaflets/Inserts: Printed materials providing patient information. These are produced by specialized printing companies.

• Tertiary Packaging: For bulk shipping.

  • Corrugated Boxes: Suppliers include International Paper Company and Smurfit Kappa Group.

The integrity of the packaging is paramount for maintaining product stability, preventing leakage, and ensuring accurate dosing. Suppliers must adhere to strict quality standards, including leachables and extractables testing, to guarantee compatibility with the ESTROGEL formulation.

Which Contract Manufacturing Organizations (CMOs) Are Likely Involved in ESTROGEL Production?

The manufacturing of finished dosage forms like ESTROGEL is often outsourced to Contract Manufacturing Organizations (CMOs) that possess specialized facilities and expertise in sterile or topical product manufacturing. These CMOs handle formulation, filling, and packaging under GMP conditions.

Identifying specific CMOs for ESTROGEL without direct disclosure from the marketing authorization holder is challenging. However, the type of manufacturing required (transdermal gel) narrows down the possibilities. Companies specializing in topical and transdermal drug product manufacturing would be the primary candidates. Examples of large global CMOs with capabilities that could include ESTROGEL production are:

• Catalent, Inc.: A major global provider of drug development and delivery solutions, with expertise in various dosage forms, including topicals.
• Recipharm AB: A leading contract manufacturer of pharmaceuticals, offering services from development to commercial manufacturing.
• Thermo Fisher Scientific (Patheon): Offers a broad range of pharmaceutical contract development and manufacturing services, including sterile and non-sterile fill-finish.
• Lonza Group AG: A global supplier to the pharmaceutical, biotech, and nutrition markets, with extensive manufacturing capabilities.

CMOs are crucial for pharmaceutical companies to scale production, manage capacity, and leverage specialized manufacturing technologies. The selection of a CMO involves extensive due diligence regarding their quality systems, regulatory compliance history, capacity, and technological capabilities.

Regulatory Landscape and Supply Chain Resilience

The supply chain for pharmaceuticals like ESTROGEL is heavily regulated. The FDA, EMA, and other health authorities require strict adherence to GMP at all stages of manufacturing, from API to finished product.

• API Sourcing: Drug manufacturers must qualify all API suppliers, ensuring they meet regulatory standards and have robust quality management systems. Site inspections and regular audits are mandatory.
• Excipient Quality: Excipients must meet pharmacopoeial standards, and their manufacturers must also be qualified. Changes in excipient suppliers often require regulatory notification or approval.
• Packaging Integrity: Packaging materials must be tested for compatibility with the drug product and for their ability to protect it from environmental factors.
• CMO Oversight: When using CMOs, the marketing authorization holder remains responsible for the quality of the finished product and must maintain oversight of the CMO's operations through quality agreements and regular audits.

Supply chain resilience is a key concern. Strategies to ensure continuity include:

• Dual Sourcing: Qualifying multiple suppliers for critical raw materials and components.
• Geographic Diversification: Sourcing from suppliers located in different regions to mitigate risks associated with localized disruptions (e.g., natural disasters, geopolitical instability).
• Inventory Management: Maintaining adequate safety stock of critical materials and finished goods.
• Supply Chain Mapping: Understanding the full chain of suppliers, including tier-2 and tier-3 suppliers, to identify potential vulnerabilities.
• Contingency Planning: Developing and regularly testing business continuity plans to address potential disruptions.

The COVID-19 pandemic highlighted the fragility of global pharmaceutical supply chains, leading to increased scrutiny of sourcing strategies and a greater emphasis on regional manufacturing capabilities. For ESTROGEL, like other pharmaceuticals, ensuring a robust and diversified supply network is essential for consistent market availability.

Key Takeaways

• API Dependency: The production of estradiol API by specialized chemical synthesis companies is foundational to ESTROGEL supply. Regulatory compliance and quality control are paramount for these suppliers.
• Excipient Diversity: ESTROGEL's transdermal gel formulation relies on a range of excipients, including solvents (ethanol, IPA), gelling agents (carbomers), neutralizing agents (TEA), emollients, and preservatives, sourced from major chemical manufacturers.
• Specialized Packaging: Precision dosing pumps and compatible primary packaging materials are critical for ESTROGEL's delivery system, often sourced from specialized medical device manufacturers.
• CMO Role: Contract Manufacturing Organizations with expertise in topical and transdermal product manufacturing likely play a significant role in the finished dosage form production of ESTROGEL.
• Regulatory Rigor: The entire supply chain is subject to stringent GMP regulations, necessitating robust quality management systems and supplier qualification processes by the marketing authorization holder.
• Resilience Imperative: Strategies such as dual sourcing, geographic diversification, and inventory management are essential to mitigate risks and ensure the continuous availability of ESTROGEL.

Frequently Asked Questions

1. What are the primary risks associated with the ESTROGEL supply chain? The primary risks include potential API supply shortages, quality issues with excipients or packaging materials, manufacturing disruptions at CMOs, and regulatory non-compliance by any supplier in the chain. Geopolitical events and natural disasters impacting key manufacturing regions also pose risks.

2. How does the regulatory environment impact ESTROGEL's supplier selection? The regulatory environment mandates that all suppliers of raw materials, components, and manufacturing services must adhere to Good Manufacturing Practices (GMP). This requires extensive qualification, auditing, and ongoing monitoring of suppliers by the pharmaceutical company to ensure product quality, safety, and efficacy.

3. Can ESTROGEL be manufactured using alternative suppliers if current ones face disruptions? Yes, pharmaceutical companies strive to qualify multiple suppliers for critical components and materials. However, switching suppliers, particularly for APIs or key excipients, often requires significant validation and regulatory approval processes, which can take time and may temporarily impact supply.

4. What is the typical shelf life of ESTROGEL, and how does it relate to supplier quality? The shelf life of ESTROGEL is determined by stability studies that evaluate the product's integrity under various storage conditions. The quality and consistency of the API, excipients, and packaging materials, all supplied by qualified vendors, are critical factors in achieving and maintaining the designated shelf life. Substandard materials can lead to premature degradation.

5. How do intellectual property rights affect the supplier landscape for ESTROGEL? While ESTROGEL itself may be protected by patents, the suppliers of generic components like estradiol API, common excipients, or standard packaging materials are generally not tied to the specific drug's composition patent unless those components are themselves patented for use in this specific formulation or delivery system. However, the marketing authorization holder's manufacturing process and specific formulation may involve proprietary knowledge, influencing CMO selection and supply agreements.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/cosmetics/good-manufacturing-practices-cosmetics/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice/good-manufacturing-practice

[3] Lubrizol Corporation. (n.d.). Carbopol Polymers. Retrieved from https://www.lubrizol.com/advanced-materials/personal-care/carbopol-polymers

[4] AptarGroup, Inc. (n.d.). Drug Delivery Solutions. Retrieved from https://www.aptar.com/markets/pharma/drug-delivery/

[5] Catalent, Inc. (n.d.). Drug Delivery Technologies. Retrieved from https://www.catalent.com/drug-delivery-technologies/